Indication

Metastatic Hormone-Naive Prostate Cancer

1 clinical trial

2 drugs

Clinical trial

UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer

Status: Active (not recruiting), Estimated PCD: 2024-04-01

Drug

Drug